Oncotarget

Reviews:

Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation

Xin-guang Liu, Yu Liu and Feng Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:3711-3723. https://doi.org/10.18632/oncotarget.12533

Metrics: PDF 3390 views  |   HTML 4655 views  |   ?  


Abstract

Xin-guang Liu1,*, Yu Liu2,* and Feng Chen1,3

1 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China

2 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China

3 Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing, China

* These authors have contributed equally to this paper

Correspondence to:

Feng Chen, email:

Keywords: soluble fibrinogen-like protein 2; immunoregulation; transplantation; hepatitis; autoimmunity

Received: July 25, 2016 Accepted: September 29, 2016 Published: October 08, 2016

Abstract

Soluble fibrinogen-like protein 2 (sFGL2) is the soluble form of fibrinogen-like protein 2 belonging to the fibrinogen-related protein superfamily. It is now well characterized that sFGL2 is mainly secreted by regulatory T cell (Treg) populations, and exerts potently immunosuppressive activities. By repressing not only the differentiation and proliferation of T cells but also the maturation of dendritic cells (DCs), sFGL2 acts largely as an immunosuppressant. Moreover, sFGL2 also induces apoptosis of B cells, tubular epithelial cells (TECs), sinusoidal endothelial cells (SECs), and hepatocytes. This mini-review focuses primarily on the recent literature with respect to the signaling mechanism of sFGL2 in immunomodulation, and discusses the clinical implications of sFGL2 in transplantation, hepatitis, autoimmunity, and tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12533